{
    "2019-01-28": [
        [
            {
                "time": "2018-01-28",
                "original_text": "格隆汇港股聚焦(1.28)︱中联重科2018年净利润预增46.4%-61.42%至19.5亿元-21.5亿元",
                "features": {
                    "keywords": [
                        "中联重科",
                        "净利润",
                        "预增",
                        "2018年"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "工业"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-28",
                "original_text": "医疗保健：板块有望随情绪修复走出反转行情 荐15股",
                "features": {
                    "keywords": [
                        "医疗保健",
                        "板块",
                        "情绪修复",
                        "反转行情"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-28",
                "original_text": "1月28日上市公司晚间公告速递",
                "features": {
                    "keywords": [
                        "上市公司",
                        "公告"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-28",
                "original_text": "复星医药(02196)乳腺癌治疗新药获美国FDA药品临床试验批准",
                "features": {
                    "keywords": [
                        "复星医药",
                        "乳腺癌",
                        "新药",
                        "FDA",
                        "临床试验"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-28",
                "original_text": "复星医药(02196.HK)：乳腺癌治疗新药临试获美国FDA批准",
                "features": {
                    "keywords": [
                        "复星医药",
                        "乳腺癌",
                        "新药",
                        "FDA",
                        "临床试验"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-28",
                "original_text": "复星医药：控股子公司获美国FDA药品临床试验批准",
                "features": {
                    "keywords": [
                        "复星医药",
                        "控股子公司",
                        "FDA",
                        "临床试验"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-28",
                "original_text": "国产单抗类似药迎来上市元年，竞争之下比拼综合实力 | 【光大医药·周报】",
                "features": {
                    "keywords": [
                        "国产单抗",
                        "类似药",
                        "上市元年",
                        "竞争",
                        "综合实力"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}